Can Elevance Offset Rising Expenses in Q4 With Higher Premiums?

Core Viewpoint - Elevance Health, Inc. (ELV) is expected to report its fourth-quarter 2025 results on January 28, 2026, with earnings estimated at $3.10 per share and revenues of $49.59 billion [1] Financial Performance - The fourth-quarter earnings estimate has seen one downward revision and no upward revisions in the past month, indicating a year-over-year decline of 19.3% in earnings, while revenues are projected to increase by 10.2% year-over-year [2] - For the full year 2025, the Zacks Consensus Estimate for Elevance's revenues is $197.98 billion, reflecting a 13% year-over-year increase, while the EPS estimate is $29.99, showing a 9.2% year-over-year decrease [3] Earnings Prediction - The current Earnings ESP for Elevance is -1.41%, and it holds a Zacks Rank of 4 (Sell), suggesting that an earnings beat is unlikely this quarter [4] Revenue Drivers - The consensus estimate for product revenues indicates a 1.5% growth from the previous year's $6.7 billion, while premiums are expected to rise by 12.3% year-over-year, contributing to overall sales growth [5] - The estimate for Commercial Individual membership suggests a 3.5% growth year-over-year, although Commercial Fee-based memberships are projected to decline by 0.4% [6] Operating Income - The Zacks Consensus Estimate for Carelon brand's operating income indicates an 8.9% year-over-year increase, driven primarily by growth in CarelonRx, while the Health Benefits segment's operating income is expected to rise by 12.1% [7] Expense Outlook - Elevated expenses are anticipated due to significant investments in digital capabilities, with total expenses expected to increase by 8.4% year-over-year in the fourth quarter [8]